Search Result

Results for "

degeneration

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (1) Apoptosis (6) Autophagy (2) Bacterial (2) Bcl-2 Family (1) Biochemical Assay Reagents (1) Casein Kinase (1) CCR (2) Cholinesterase (ChE) (1) Complement System (6) Dopamine Receptor (1) EAAT (2) Endogenous Metabolite (1) Endothelin Receptor (1) Estrogen Receptor/ERR (1) FGFR (2) Fluorescent Dye (1) HSP (1) Interleukin Related (2) Keap1-Nrf2 (1) MyD88 (1) NF-κB (2) PDGFR (3) Phospholipase (3) PPAR (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (2) Src (2) SRPK (1) VEGFR (13) YAP (2) α-synuclein (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (13) Endocrinology (1) Infection (2) Inflammation/Immunology (11) Metabolic Disease (10) Neurological Disease (18)

By Targets:

Amyloid-β (1)

Apoptosis (6)

Autophagy (2)

Bacterial (2)

Bcl-2 Family (1)

Biochemical Assay Reagents (1)

Casein Kinase (1)

CCR (2)

Cholinesterase (ChE) (1)

Complement System (6)

Dopamine Receptor (1)

EAAT (2)

Endogenous Metabolite (1)

Endothelin Receptor (1)

Estrogen Receptor/ERR (1)

FGFR (2)

Fluorescent Dye (1)

HSP (1)

Interleukin Related (2)

Keap1-Nrf2 (1)

MyD88 (1)

NF-κB (2)

PDGFR (3)

Phospholipase (3)

PPAR (1)

Ser/Thr Protease (1)

Small Interfering RNA (siRNA) (2)

Src (2)

SRPK (1)

VEGFR (13)

YAP (2)

α-synuclein (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (13)

Endocrinology (1)

Infection (2)

Inflammation/Immunology (11)

Metabolic Disease (10)

Neurological Disease (18)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116098

Anecortave AL-4940	Biochemical Assay Reagents	Cancer
Anecortave (AL-4940) is an angiogenesis inhibitor. Anecortave is indicated for the study of exudative (wet) age-related macular degeneration as well as retinal tumors .

HY-145917

SARM1-IN-2	Others	Neurological Disease
SARM1-IN-2 is a SARM1 inhibitor extracted from patent WO2019236890A1 example 82. SARM1-IN-2 can be used for the research of axonal degeneration .

HY-P99629

Galegenimab FHTR 2163; RG 6147; RO 7171009	Ser/Thr Protease	Neurological Disease
Galegenimab (FHTR 2163; RG 6147; RO 7171009), an anti-High-temperature requirement A1 (HTRA1) antibody fragment. Galegenimab can be used for age-related macular degeneration (AMD) research .

HY-P3204

POT-4 AL-78898A	Complement System	Metabolic Disease
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research

HY-124717

YC-001	Endogenous Metabolite	Others
YC-001 is an inverse agonist and antagonist of rod opsin. YC-001 reversibly binds rod opsin and stabilizes the rod opsin structure. YC-001 protects mice from bright light-induced retinal degeneration. YC-001 has the potential for the research of retinal degeneration .

HY-136788A

ALK4290 dihydrochloride AKST4290 dihydrochloride	CCR	Inflammation/Immunology
ALK4290 dihydrochloride (AKST4290 dihydrochlorid) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .

HY-P3204A

POT-4 TFA AL-78898A TFA	Complement System	Metabolic Disease
POT-4 TFA (AL-78898A TFA), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 TFA can be used for age-related macular degeneration research .

HY-110195

Smurf1-IN-A01 1 Publications Verification A01	HSP Interleukin Related MyD88 NF-κB Estrogen Receptor/ERR	Others
Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration .

HY-114653

SRPIN803	Casein Kinase SRPK	Cancer
SRPIN803 is a potent CK2 and SRPK1 dual inhibitor, with IC₅₀s of 203 nM and 2.4 μM, respectively. SRPIN803 exhibits antiangiogenic activity. SRPIN803 can be used for the research of age-related macular degeneration .

HY-107525

(±)-HIP-A	EAAT	Neurological Disease
(±)-HIP-A is a non-competitive excitatory amino acid transporter (EAAT) blocker that effectively blocks Glu uptake (IC₅₀=17-18 μM). (±)-HIP-A is also a lead compound against ischemia-induced neuronal degeneration. (±)-HIP-A can be used in the study of neurological diseases .

HY-107524

(±)-HIP-B	EAAT	Neurological Disease
(±)-HIP-B is a non-competitive excitatory amino acid transporter (EAAT) blocker that effectively blocks Glu uptake (IC₅₀=17-18 μM). (±)-HIP-B is also a lead compound against ischemia-induced neuronal degeneration. (±)-HIP-B can be used in the study of neurological diseases .

HY-P99576

Tarcocimab OG1953	VEGFR	Others
Tarcocimab (OG1953) is a humanized anti-VEGFA monoclonal antibody (IgG1 type). Tarcocimab is available for research in retinal vein occlusion (RVO) and wet age-related macular degeneration (AMD).

HY-B0835S

Fenobucarb-d3	Apoptosis	Neurological Disease
Fenobucarb-d₃ is the deuterium labeled Fenobucarb. Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis[1].

HY-136788

ALK4290 AKST4290	CCR	Neurological Disease Inflammation/Immunology
ALK4290 (AKST4290) is a potent and orally active CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a K_i of 3.2 nM for hCCR3 . ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism .

HY-P9951

Ranibizumab RG-6321	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P99298

Lampalizumab RG 7417; TNX 234; Anti-CFD Recombinant Antibody	Complement System	Inflammation/Immunology
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .

HY-P9951A

Ranibizumab (anti-VEGF) RG-6321 (anti-VEGF)	VEGFR	Cardiovascular Disease
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165) . Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research .

HY-P99905

Efdamrofusp alfa	VEGFR	Cardiovascular Disease Neurological Disease
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions .

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-W010410

Oct-1-en-3-ol	Others	Neurological Disease Metabolic Disease
Oct-1-en-3-ol, a fatty acid fragrant, is a self-stimulating oxylipin messenger. Oct-1-en-3-ol serves as a signaling molecule in plant cellular responses, plant-herbivore interactions, and plant-plant interactions. Oct-1-en-3-ol causes dopamine neuron degeneration through disruption of dopamine handling .

HY-19210

SB-209670	Endothelin Receptor	Cardiovascular Disease
SB-209670 is an extremely potent and highly specific non-peptide, subnanomolar endothelin (ET) receptor antagonist. SB 209670 selectively inhibits binding of 125I-labeled ET-1 to cloned human ET receptor subtypes ETA and ETB (K_i=0.2 and 18 nM, respectively). SB 209670 produces a dose-dependent reduction in blood pressure in hypertensive rats, protects from ischemia-induced neuronal degeneration in a gerbil stroke model, and attenuates neointima formation following rat carotid artery balloon angioplasty .

HY-151536

meso-Benzothiazole-BODIPY 505/515	Fluorescent Dye	Neurological Disease
meso-Benzothiazole-BODIPY 505/515 is a boron dipyrromethenes (BODIPY) -based fluorescent probedegeneration diseases .

HY-114775

RCGD423 1 Publications Verification	Interleukin Related	Neurological Disease Inflammation/Immunology
RCGD423 is a gp130 modulator, which prevents articular cartilage degeneration and promotes repair.

HY-16467

Squalamine lactate MSI-1256F	Bacterial	Infection Cardiovascular Disease Cancer
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.

HY-A0296

Chlormethiazole hydrochloride Clomethiazole hydrochloride	Others	Neurological Disease
Clomethiazole hydrochloride is a anticonvulsant. Clomethiazole hydrochloride is neuroprotective and prevents the degeneration of serotonergic nerve terminals induced by 3,4-methylenedioxymethamphetamine (MDMA) .

HY-P99402

Rinucumab REGN 2176	PDGFR	Metabolic Disease
Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration .

HY-N6812

Karacoline	NF-κB	Endocrinology
Karacoline, a diterpene alkaloid found in the plant Aconitum kusnezoffii, reduces degradation of the extracellular matrix (ECM) in intervertebral disc degeneration (IDD) via the NF-κB signaling pathway .

HY-15492

AG-13958 AG-013958	VEGFR	Cardiovascular Disease
AG-13958 (AG-013958), a potent VEGFR tyrosine kinase inhibitor, is used for treatment of choroidal neovascularization associated with age-related macular degeneration (AMD) .

HY-109561

Pegaptanib sodium EYE001; NX1838	VEGFR	Metabolic Disease Inflammation/Immunology
Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .

HY-124876

SynuClean-D SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-B0835

Fenobucarb	Apoptosis	Cardiovascular Disease Neurological Disease
Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis. Fenobucarb is a possible risk factor to cardiovascular and cerebrovascular systems in animals .

HY-W014700

Glycyl-L-glutamic acid	Cholinesterase (ChE)	Neurological Disease
Glycyl-L-glutamic acid is a neurotrophic factor (NF) in vivo, and exerts function of maintenance of AChE content and activity. Glycyl-L-glutamic acid doesn’t act directly on AChE synthesis, and may prevent preganglionic neuronal degeneration .

HY-147080

Avacincaptad pegol sodium ARC1905	Complement System	Others
Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).

HY-163403

VEGFR-2-IN-43	VEGFR	Cardiovascular Disease Cancer
VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC₅₀ of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research .

HY-153484A

Bevasiranib sodium	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-153484

Bevasiranib	VEGFR Small Interfering RNA (siRNA)	Others
Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).

HY-150069

UBX1325	Bcl-2 Family Apoptosis	Metabolic Disease
UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR) .

HY-N7270

Apigenin-7-diglucuronide	Others	Inflammation/Immunology
Apigenin-7-diglucuronide is a flavonoid glycoside and is present in an assortment of medicinal plants with anti-inflammatory or ant-oxidant activities. Apigenin-7-diglucuronide protects retinas against bright light-induced photoreceptor degeneration through the inhibition of retinal oxidative stress and inflammation .

HY-153183

Lp-PLA2-IN-12	Phospholipase	Cardiovascular Disease Neurological Disease
Lp-PLA2-IN-12 (compound 19) is an Lp-PLA2 inhibitor. Lp-PLA2-IN-12 can be used for the study of neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular disease including atherosclerosis .

HY-B0146

Verteporfin Maximum Cited Publications 142 Publications Verification CL 318952	YAP Apoptosis Autophagy	Cancer
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-108801A

Aflibercept (VEGF Trap)	VEGFR	Cardiovascular Disease Metabolic Disease
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease .

HY-136234

9-cis-β-Carotene	Others	Others
9-cis-β-Carotene, a precursor of retinal, is cleaved by beta-carotene oxygenase 1 (BCMO1) to produce 9-cis-retinal. 9-cis-β-Carotene inhibits photoreceptor degeneration and restores retinal function in vivo. 9-cis-β-Carotene has the potential for the study of congenital stationary night blindness and fundus albipunctatus .

HY-101446

HIOC
HIOC is a potent and selective activator of TrkB (tropomyosin related kinase B) receptor. HIOC can pass the blood-brain and blood-retinal barriers.HIOC activates TrkB/ERK pathway and decreases neuronal cell apoptosis. HIOC attenuates early brain injury after SAH (subarachnoid hemorrhage). HIOC shows protective activity in an animal model for light-induced retinal degeneration .

HY-153560

Lp-PLA2-IN-14	Phospholipase	Neurological Disease
Lp-PLA2-IN-14 (Compound 19) is an Lp-PLA2 inhibitor with a pIC₅₀ of 8.4 against rhLp-PLA2. Lp-PLA2-IN-14 can be used for the research of neurodegenerative related diseases, such as Alzheimer Disease (AD), glaucoma, age-related macular degeneration (AMD) or cardiovascular diseases including atherosclerosis and the like .

HY-153903

RASP-IN-1	Others	Others
RASP-IN-1 (compound A) is a lipophili ccompound used for macular degeneration inhibition. RASP-IN-1 is biologically active in the retina of the rabbit's eye. Thirty minutes after IP treatment with ¹⁴C-RASP-IN-1 (10 mg/kg)，the C_max amount of ¹⁴C-RASP-IN-1 in the posterior eye cup is 14.36 μg/g in mice model .

HY-N2292

Kinsenoside 1 Publications Verification	Keap1-Nrf2 Apoptosis	Inflammation/Immunology
Kinsenoside is the main active ingredient of the genus plant, and has various biological activities. Kinsenoside and Nrf2 depend on the protection of nuclear cells (NPCs), which significantly reduces their ability to survive. Kinsenoside Active NPC Medium AKT-ERK1/2-Nrf2 Signal passage, Prevent physical decline, aging, harmonious physical function impairment. Kinsenoside can improve the puncture guide model for intermediate vertebral wall discharge (IDD).

HY-N11499

Myricetin 3-O-α-L-arabinopyranoside	Bacterial	Infection Inflammation/Immunology
Myricetin 3-O-α-L-arabinopyranoside is a quercetin derivative and plant flavonoid with antioxidant, antibacterial and antiurease effects. Myricetin 3-O-α-L-arabinopyranoside inhibits A2E photooxidation-induced RPE cell death. Myricetin 3-O-α-L-arabinopyranoside is protective against retinal degeneration and protects against blue light (BL)-induced damage in RPE cells and mouse models .

HY-B0146R

Verteporfin (Standard) CL 318952 (Standard)	YAP Apoptosis Autophagy	Cancer
Verteporfin (Standard) is the analytical standard of Verteporfin. This product is intended for research and analytical applications. Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation .

HY-148370

IONIS-FB-LRx RG6299	Complement System	Others
IONIS-FB-LRx is a specific antisense oligonucleotide (ASO) targeting complement factor B (CFB). IONIS-FB-LRx effectively reduces circulating levels of CFB. IONIS-FB-LRx can be used for geographic atrophy (GA) research .

Cat. No.	Product Name

HY-L070

Neuroprotective Compound Library

1058 compounds

Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases.

MCE offers a unique collection of 1058 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

HY-L086

Neurodegenerative Disease-related Compound Library

2228 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 2228 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

HY-L034

Anti-Aging Compound Library

4352 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4352 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Target	Research Area